Everolimus treatment option for tuberous sclerosis patients

NewsGuard 100/100 Score

Researchers have shown that the immunosuppressant everolimus provides a potential new treatment option for patients with tuberous sclerosis and associated angiomyolipomas.

In a randomized, phase III trial, the drug was significantly more effective than placebo at reducing angiomyolipoma volume and also demonstrated an acceptable safety profile, they report.

"This finding opens an alternative avenue for the treatment of patients who are not amenable to surgical intervention," say John Bissler (Cincinnati Children's Hospital Medical Center, Ohio, USA) and colleagues. They point out that 40% of the patients in their trial had already undergone an invasive surgical procedure but still required intervention, highlighting the limitations of this approach.

As reported in The Lancet, 33 (42%) of 79 patients who received everolimus 10 mg/day had a reduction in angiomyolipoma of 50% or more and were free of angiomyolipoma progression after a median drug exposure of 38 weeks, while no such response was observed in the placebo group.

In an accompanying commentary, Prasanna Sooriakumaran and Christopher Anderson from St George's National Health Service Trust in London, UK, say this is "a highly significant and, we believe, clinically significant finding."

The median time to angiomyolipoma response was 2.9 months and the treatment effect remained consistent when patients were stratified by strata, gender, age, or race.

Six months after baseline assessment, angiomyolipomas had not progressed in 98% of patients who received everolimus, compared with 83% of the placebo group. And after 12 months, 92% of those who received everolimus remained progression-free, while only 25% who received placebo were progression-free.

The most common adverse events with everolimus treatment were stomatitis, nasopharyngitis, and acne-like lesions, which occurred in 48%, 24%, and 22% of patients, compared with 8%, 31%, and 5% of those who took the placebo treatment. However, these adverse events were mostly mild and generally managed while patients continued everolimus treatment, reports the team.

"We congratulate the authors of this study," say Soorakumaran and Anderson. "Their results are promising and are likely to herald a new approach to the treatment of this rare but serious disease."

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, August 23). Everolimus treatment option for tuberous sclerosis patients. News-Medical. Retrieved on May 18, 2024 from https://www.news-medical.net/news/20130125/Everolimus-treatment-option-for-tuberous-sclerosis-patients.aspx.

  • MLA

    Robertson, Sally. "Everolimus treatment option for tuberous sclerosis patients". News-Medical. 18 May 2024. <https://www.news-medical.net/news/20130125/Everolimus-treatment-option-for-tuberous-sclerosis-patients.aspx>.

  • Chicago

    Robertson, Sally. "Everolimus treatment option for tuberous sclerosis patients". News-Medical. https://www.news-medical.net/news/20130125/Everolimus-treatment-option-for-tuberous-sclerosis-patients.aspx. (accessed May 18, 2024).

  • Harvard

    Robertson, Sally. 2018. Everolimus treatment option for tuberous sclerosis patients. News-Medical, viewed 18 May 2024, https://www.news-medical.net/news/20130125/Everolimus-treatment-option-for-tuberous-sclerosis-patients.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase II clinical trial evaluates the safety and efficacy of a Muse cell-based product in patients with ALS